Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics, |
RCV001706752 | SCV001934221 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 3 | 2020-10-06 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV003238377 | SCV002011055 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003163797 | SCV003861268 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-11-04 | criteria provided, single submitter | clinical testing | The p.E122D variant (also known as c.366A>C), located in coding exon 2 of the RAD51C gene, results from an A to C substitution at nucleotide position 366. The glutamic acid at codon 122 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |